

PANCREATIC DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
 ROOM: ROSSETTI
 SATURDAY MAY 4, 2019, 10:45 AM – 11:40 AM

CO-CHAIRS : DR. DAN RENOUF & DR. ALICE WEI
 SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with pancreatic malignancies in Canada.
- To identify clinical trial research opportunities in pancreatic malignancies within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to pancreatic malignancies.
- To integrate and apply new clinical trial methodologies in pancreatic malignancies in the Canadian Cancer Trials Group research agenda.
- To provide a learning and mentoring environment supportive to new investigators.

10:45 am	Welcome	Dr. D. Renouf Dr. A. Wei
10:50 am	PA.6 (ACCORD 24): Randomized Multicenter Phase III Comparison of Adjuvant Chemotherapy with Gemcitabine versus a Combination of 5-Fluorouracil, Leucovorin, Irinotecan And Oxaliplatin (mFOLFIRINOX) in Patients with Resected Pancreatic Adenocarcinoma	Dr. J. Biagi Dr. A. Wei
10:55 am	Alliance A021806: Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	Dr. D. Renouf Dr. A. Wei

11:05 am	PA.7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs. Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma	Dr. D. Renouf
11:15 am	Concept: FLIP-PANC: 5-Fluorouracil, nanoliposomal Irinotecan, and Palbociclib in Patients with advanced pancreatic ductal AdeNocarcinoma and CDKN2A mutations	Dr. E. Tsang Dr. D. Renouf
11:25 am	COMPASS/PANGEN Update	Dr. D. Renouf
11:30 am	Intergroup Task Force Update	Dr. D. Renouf Dr. A. Wei
11:40 am	Meeting Adjourned	